Radioprotection of salivary glands by S-2-(3-aminopropylamino)- ethylphosphorothioic (amifostine) obtained in a rabbit animal model

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 1, 1999, Pages 181-186

  Bohuslavizki, Karl H ^a   Klutmann, Susanne ^a   Jenicke, Lars ^b   Brenner, Winfried ^b   Feyerabend, Bernd ^b   Henze, Eberhard ^b   Clausen, Malte ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Amifostine; High dose radioiodine treatment; Rabbit animal model; Radioprotection; Salivary glands

Indexed keywords

AMIFOSTINE; IODINE 131; PERTECHNETIC ACID TC 99M; RADIOACTIVE IODINE;

ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; HEAD AND NECK CANCER; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIATION DOSE; RADIATION PROTECTION; SALIVARY GLAND; SALIVARY GLAND SCINTISCANNING; SCINTILLATION CAMERA; THYROID CANCER; TREATMENT OUTCOME;

AMIFOSTINE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; IODINE RADIOISOTOPES; MALE; RABBITS; RADIATION-PROTECTIVE AGENTS; RADIOBIOLOGY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SALIVARY GLANDS; SODIUM PERTECHNETATE TC 99M;

EID: 0032807404     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00160-1     Document Type: Article

References (31)

1. Baum B.J. Principles of saliva secretion. Ann NY Acad Sci. 694:1993;17-23.
2. --co-transport system. J Clin Invest. 79:1987;1310-1313.
3. Albrecht H.H., Creutzig H. Funktionsszintigraphie der Speicheldrüsen nach hochdosierter Radiojodtherapie. Fortschr Röntgenstr. 125:1976;546-551.
4. 131I). Sandler M.P., Patton J.A., Coleman R.E., et al. Diagnostic nuclear medicine. 1995;959-989 Williams & Wilkins, Baltimore.
5. Bohuslavizki K.H., Brenner W., Tinnemeyer S., et al. Normal data base for quantitative salivary gland scintigraphy. Radiol Oncol. 29:1995;297-305.
6. Clarke S.E.M. Radioiodine therapy of the thyroid. Murray I.P.C., Ell P.J. Nuclear medicine in clinical diagnosis and therapy. 1994;833-845 Churchill Livingstone, Edinburgh.
7. Alexander C., Bader J.A., Schaefer A., et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med. 39:1998;1551-1554.
8. Bohuslavizki K.H., Brenner W., Lassmann S., et al. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun. 17:1996;681-686.
9. Bohuslavizki K.H., Brenner W., Klutmann S., et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med. 39:1998;1237-1242.
10. Menard T.W., Izutsu K.T., Ensign W.Y., et al. Radioprotection by WR-2721 of gamma-irradiated rat parotid gland: Effect on gland weight and secretion at 8-10 days post irradiation. Int J Radiat Oncol Biol Phys. 10:1984;1555-1559.
11. Pratt N.E., Sodicoff M., Liss J., et al. Radioprotection of the rat parotid gland by WR-2721 S-2-3-aminopropylaminoethyl phosphorothioate morphology at 60 days post irradiation. Int J Radiat Oncol Biol Phys. 6:1980;431-436.
12. Sodicoff M., Conger A.D., Trepper P., et al. Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res. 76:1978;317-326.
13. Sodicoff M., Conger A.D., Pratt N.E., et al. Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res. 76:1978;172-179.
14. Bohuslavizki K.H., Klutmann S., Brenner W., et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study. J Clin Oncol. 16:1998;3542-3549.
15. Hübner R.H., Bohuslavizki K.H., Brenner W., et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy investigated in a new rabbit animal model. Radiol Oncol. 31:1997;279-285.
16. Sachs L. Applied statistics - A handbook of techniques. 2nd ed. 1984;Springer, New York.
17. Patt H.M., Tyree E.B., Straube R.L., et al. Technical papers. Cystein protection against X irradiation. Science. 110:1949;213-214.
18. Wasserman T.H., Phillips T.L., Ross G., et al. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials. 4:1981;3-6.
19. Yuhas J.M., Spellman J.M., Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials. 3:1980;211-216.
20. Rasey J.S., Krohn K.A., Menard T.W., et al. Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys. 12:1968;1487-1490.
21. Rasey J.S., Spence A.M., Badger C.C., et al. Specific protection of different normal tissues. Pharmacol Ther. 39:1988;33-43.
22. Rasey J.S., Krohn K.A., Grunbaum Z., et al. Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)-ethylphosphorothioic acid (WR-3689). Radiat Res. 106:1986;366-379.
23. Utley J.F., Phillips T.L., Kane L.J. Protection of normal tissues by WR-2721 during fractionated irradiation. Int J Radiat Oncol Biol Phys. 1:1976;699-703.
24. Utley J.F., Quinn C.A., White F.C., et al. Protection of normal tissue against late radiation injury by WR-2721. Radiat Res. 85:1981;408-415.
25. Rasey J.S., Grunbaum Z., Krohn K.A., et al. Biodistribution of the radioprotective drug S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913). Radiat Res. 102:1986;130-137.
26. Washburn L.C., Carlton J.E., Hayes R.L., et al. Distribution of WR-2721 in normal and malignant tissues of mice and rats bearing solid tumors: Dependence on tumor type, drug dose and species. Radiat Res. 59:1974;475-483.
27. 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res. 68:1976;284-291.
28. Dreyer J.O., Sakuma Y., Seifert G. Die Strahlen-Sialadenitis - Stadieneinteilung und Immunhistologie. Pathologe. 10:1989;165-170.
29. Abot K., Brunk U., Jung B., et al. Morphologic and histochemical studies on the differing radiosensitivity of ductular and acinar cells of the rat submandibular gland. Virchows Arch Cell Pathol. 45:1984;443-460.
30. Seifert G., Geier W. Zur Pathologie der Strahlen-Sialadenitis. Z Laryng Rhinol. 50:1971;376-388.
31. Yuhas J.M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 40:1980;1519-1524.